|
1.
|
|
20 p, 6.0 MB |
Multi-Smart and Scalable Bioligands-Free Nanomedical Platform for Intratumorally Targeted Tambjamine Delivery, a Difficult to Administrate Highly Cytotoxic Drug
/
Pérez-Hernández, Marta (Institut d'Investigació Biomèdica de Bellvitge) ;
Cuscó, Cristina (Nanobiotechnological Polymers Division) ;
Benítez-García, Cristina (Institut d'Investigació Biomèdica de Bellvitge) ;
Bonelli, Joaquin (Nanobiotechnological Polymers DivisionBusiness Park) ;
Nuevo-Fonoll, Marina (Universitat de Barcelona. Departament de Patologia i Terapèutica Experimental) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez-García, David (Institut d'Investigació Biomèdica de Bellvitge) ;
Arias-Betancur, Alain (Universidad de La Frontera) ;
García-Valverde, María (Universidad de Burgos) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Quesada, Roberto (Universidad de Burgos) ;
Rocas, Josep (Nanobiotechnological Polymers Division) ;
Soto-Cerrato, Vanessa (Institut d'Investigació Biomèdica de Bellvitge) ;
Pérez-Tomás, Ricardo (Universitat de Barcelona) ;
Universitat Autònoma de Barcelona
Cancer is one of the leading causes of mortality worldwide due, in part, to limited success of some current therapeutic approaches. The clinical potential of many promising drugs is restricted by their systemic toxicity and lack of selectivity towards cancer cells, leading to insufficient drug concentration at the tumor site. [...]
2021 -  10.3390/biomedicines9050508
Biomedicines, Vol. 9 (may 2021)
|
|
|
2.
|
|
10 p, 1.7 MB |
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis
/
París-Coderch, Laia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Erazo, Tatiana (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Muñoz-Guardiola, Pau (Ability Pharmaceuticals) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Boloix, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Alfón, José (Ability Pharmaceuticals) ;
Pérez-Montoyo, Héctor (Ability Pharmaceuticals) ;
Yeste-Velasco, Marc (Ability Pharmaceuticals) ;
Domènech, Carles (Ability Pharmaceuticals) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez de Toledo Codin, Josep (Vall d'Hebron Institut d'Oncologia) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Gallego, Soledad (Vall d'Hebron Institut d'Oncologia) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Neuroblastoma is the leading cause of cancer death in children aged 1 to 4 years. Particularly, five-year overall survival for high-risk neuroblastoma is below 50% with no curative options when refractory or relapsed. [...]
2020 - 10.1038/s41419-020-02986-w
Cell death and disease, Vol. 11 (september 2020)
|
|
|
3.
|
|
13 p, 1.3 MB |
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
/
Alcon, Clara (Institut de Bioenginyeria de Catalunya) ;
Manzano-Muñoz, Albert (Institut de Bioenginyeria de Catalunya) ;
Prada, Estela (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Català-Mora, Jaume (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Guillén, Gabriela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Samitier, Josep (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Villanueva, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Montero, Joan (Institut de Bioenginyeria de Catalunya) ;
Universitat Autònoma de Barcelona
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. [...]
2020 - 10.1038/s41419-020-02887-y
Cell death and disease, Vol. 11 (august 2020)
|
|
|
4.
|
|
17 p, 3.9 MB |
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models
/
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Riley, Misha (Massachusetts General Hospital (Boston)) ;
Servidei, Tiziana (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Riccardi, Riccardo (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martini, Maurizio (Catholic University of Sacred Heart) ;
Ruggiero, Antonio (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Sánchez de Toledo Codin, Josep (Vall d'Hebron Institut d'Oncologia) ;
Gallego, Soledad (Vall d'Hebron Institut d'Oncologia) ;
Bové, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hooker, Jacob M. (Massachusetts General Hospital (Boston)) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Pediatric ependymoma (EPN) is a highly aggressive tumor of the central nervous system that remains incurable in 40% of cases. In children, the majority of cases develop in the posterior fossa and can be classified into two distinct molecular entities: EPN posterior fossa A (PF-EPN-A) and EPN posterior fossa B (PF-EPN-B). [...]
2020 - 10.3390/cancers12071922
Cancers, Vol. 12 (july 2020)
|
|
|
5.
|
|
|
6.
|
|
15 p, 1.7 MB |
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications
/
Carrillo-Reixach, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Torrens, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Simón-Coma, Marina (Institut Germans Trias i Pujol) ;
Royo, Laura (Institut Germans Trias i Pujol) ;
Domingo-Sàbat, Montse (Institut Germans Trias i Pujol) ;
Abril-Fornaguera, Jordi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Akers, N. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica)) ;
Sala Llinas, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ragull, Sonia (Institut Germans Trias i Pujol) ;
Arnal, Magdalena (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Villalmanzo, Núria (Institut Germans Trias i Pujol) ;
Cairo, Stefano (Instituto di Ricerca Pediatrica. Corso Stati Uniti 4) ;
Villanueva, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Kappler, R. (Department of Pediatric Surgery. Dr. von Hauner Children's Hospital. Ludwig-Maximilians-University Munich) ;
Garrido-Pontnou, Marta (Hospital Universitari Vall d'Hebron) ;
Guerra, Laura (Hospital Universitario La Paz (Madrid)) ;
Sábado, Constantino (Hospital Universitari Vall d'Hebron) ;
Guillén, Gabriela (Hospital Universitari Vall d'Hebron) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Piñeyro, David (Institut Germans Trias i Pujol) ;
Vázquez-Vitali, María (Institut Germans Trias i Pujol) ;
Kuchuk, O. (Mount Sinai Liver Cancer Program. Divisions of Liver Diseases. Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai) ;
Mateos, María Elena (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Ramírez, G. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Santamaría, María (Hospital Universitario La Paz (Madrid)) ;
Mozo, Y. (Hospital Universitario La Paz (Madrid)) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Grotzer, M. (Department of Pediatric Oncology. University Children's Hospital Zurich. University of Zurich) ;
Branchereau, S. (Bicêtre Hospital) ;
de Andoin, N. G. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
López-Ibor, B. (Department of Pediatric Hematology and Oncology. HM Montepríncipe Hospital) ;
López-Almaraz, R. (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Salinas, J. A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Torres, B. (Hospital Universitari i Politècnic La Fe (València)) ;
Hernández, Francisco (Hospital Universitario La Paz (Madrid)) ;
Uriz, J. J. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Fabre, M. (Department of Pathology. Hôpital Universitaire Necker-Enfants Malades. Assistance Publique-Hôpitaux de Paris. Université Paris Descartes) ;
Blanco, J. (Joan) (Joan) (Universitat de Vic - Universitat Central de Catalunya) ;
Paris, C. (Stem Cell Transplant Unit. Hospital Luis Calvo Mackenna) ;
Bajčiová, V. (Department of Pediatric Oncology. Childrens University Hospital Brno) ;
Laureys, G. (Ghent University Hospital. (Bèlgica)) ;
Masnou, Helena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Clos, Ariadna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Beléndez, Cristina (Hospital General Universitario Gregorio Marañón) ;
Guettier, C. (Bicêtre Hospital) ;
Sumoy, Lauro (Institut Germans Trias i Pujol) ;
Planas, Ramón (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Jordà, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Nonell, Lara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Czauderna, P. (Department of Surgery and Urology for Children and Adolescents. Medical University of Gdansk) ;
Morland, B. (Birmingham Women's Hospital) ;
Sia, D. (Mount Sinai Liver Cancer Program. Divisions of Liver Diseases. Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai) ;
Losic, B. (Icahn Institute for Data Science and Genomic Technology (Nova York, Estats Units d'Amèrica)) ;
Buendia, M. A. (INSERM. UMR 1193. Paul-Brousse Hospital. Hepatobiliary Centre) ;
Sarrias, Maria-Rosa (Institut Germans Trias i Pujol) ;
Llovet, J. M. (Institució Catalana de Recerca i Estudis Avançats) ;
Armengol, Carolina (Institut Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. [...]
2020 - 10.1016/j.jhep.2020.03.025
Journal of Hepatology, Vol. 73 Núm. 2 (august 2020) , p. 328-341
|
|
|
7.
|
|
1.1 MB |
Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer
/
Boloix, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez de Toledo Codin, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
In recent decades, biomedical research has focused on understanding the functionality of the human translated genome, which represents a minor part of all genetic information transcribed from the human genome. [...]
2019 - 10.3389/fonc.2019.01173
Frontiers in Oncology, Vol. 9 (november 2019)
|
|
|
8.
|
|
14 p, 787.7 KB |
A High-Throughput Screening Identifies MicroRNA Inhibitors That Influence Neuronal Maintenance and/or Response to Oxidative Stress
/
Pallarès-Albanell, Joan (Centre de Regulació Genòmica) ;
Zomeño-Abellán, M. Teresa (Centre de Regulació Genòmica) ;
Escaramís, Georgia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Pantano, Lorena (Harvard T.H. Chan School of Public Health. Department of Biostatistics) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron) ;
Martí, Eulàlia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Universitat Autònoma de Barcelona
Small non-coding RNAs (sncRNAs), including microRNAs (miRNAs) are important post-transcriptional gene expression regulators relevant in physiological and pathological processes. Here, we combined a high-throughput functional screening (HTFS) platform with a library of antisense oligonucleotides (ASOs) to systematically identify sncRNAs that affect neuronal cell survival in basal conditions and in response to oxidative stress (OS), a major hallmark in neurodegenerative diseases. [...]
2019 - 10.1016/j.omtn.2019.06.007
Molecular Therapy. Nucleic Acids, Vol. 17 (june 2019) , p. 374-387
|
|
|
9.
|
|
13 p, 6.2 MB |
Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma
/
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Boloix, Ariadna (Institut de Ciència de Materials de Barcelona) ;
Masiá, Núria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
París-Coderch, Laia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Piskareva, Olga (Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital. Molecular and Cellular Therapeutics) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Henrich, Kai-Oliver (German Cancer Research Center (DKFZ). Neuroblastoma Genomics Group) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Westermann, Frank (German Cancer Research Center (DKFZ). Neuroblastoma Genomics Group) ;
Stallings, Raymond L. (Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital. Molecular and Cellular Therapeutics) ;
Sábado, Constantino (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de Toledo, Josep Sánchez (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Santamaría, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona ;
Hospital Universitari Vall d'Hebron
The online version of this article (10. 1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users.
Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. [...]
2019 - 10.1007/s00018-019-03041-4
Cellular and Molecular Life Sciences, Vol. 76 (february 2019) , p. 2231-2243
|
|
|
10.
|
|
12 p, 1.7 MB |
Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma : the oncogenic role of the ligands
/
Almazán-Moga, Anna (Hospital Universitari Vall d'Hebron) ;
Zarzosa, Patricia (Hospital Universitari Vall d'Hebron) ;
Molist, C. (Hospital Universitari Vall d'Hebron) ;
Velasco, Pablo (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Pyczek, J. (Institute of Human Genetics, University of Goettingen) ;
Simon-Keller, K. (Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg) ;
Giralt, Irina (Hospital Universitari Vall d'Hebron) ;
Vidal, I (Hospital Universitari Vall d'Hebron) ;
Navarro, N. (Hospital Universitari Vall d'Hebron) ;
Segura, M. F. (Hospital Universitari Vall d'Hebron) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron) ;
Navarro, Susanna (Universitat de València. Departament de Patologia) ;
Tirado, O. M. (Institut d'Investigació Biomèdica de Bellvitge) ;
Ferreres Piñas, Joan Carles (Hospital Universitari Vall d'Hebron) ;
Santamaria, A. (Hospital Universitari Vall d'Hebron) ;
Rota, R. (Ospedale Pediatrico Bambino Gesù, IRCCS) ;
Hahn, H. (Institute of Human Genetics, University of Goettingen) ;
Sánchez de Toledo, J.. (Hospital Universitari Vall d'Hebron) ;
Roma, Josep (Hospital Universitari Vall d'Hebron) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron)
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH) pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway in RMS is not well understood. [...]
2017 - 10.1038/bjc.2017.305
British Journal of Cancer, Vol. 117 (09 2017) , p. 1314-1325
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
